ADC Therapeutics (ADCT) News Today → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free ADCT Stock Alerts $4.57 +0.16 (+3.63%) (As of 02:38 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineADC Therapeutics SA: ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conferencefinanznachrichten.de - May 9 at 8:45 AMADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conferenceglobenewswire.com - May 9 at 7:15 AMADC Therapeutics (NYSE:ADCT) Price Target Lowered to $8.00 at HC Wainwrightamericanbankingnews.com - May 8 at 5:50 AMBuy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlookmarkets.businessinsider.com - May 7 at 11:19 PMADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 7 at 1:17 PMHC Wainwright Cuts ADC Therapeutics (NYSE:ADCT) Price Target to $8.00marketbeat.com - May 7 at 8:40 AMADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Resultsmarketbeat.com - May 7 at 8:30 AMADC Therapeutics SA: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrantsfinanznachrichten.de - May 6 at 7:22 PMADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrantsfinance.yahoo.com - May 6 at 7:22 PMADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024investorplace.com - May 6 at 12:05 PMADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updatesglobenewswire.com - May 6 at 6:10 AMADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphomaglobenewswire.com - May 6 at 6:00 AMADC Therapeutics (ADCT) to Release Quarterly Earnings on Mondayamericanbankingnews.com - May 4 at 2:36 AMADC Therapeutics (ADCT) Set to Announce Earnings on Mondaymarketbeat.com - May 2 at 10:39 AMADC Therapeutics Makes Grants to New Employees Under Inducement Planglobenewswire.com - May 1 at 4:05 PMADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024finance.yahoo.com - May 1 at 7:53 AMADCT ADC Therapeutics SAseekingalpha.com - April 30 at 11:14 AMHC Wainwright Comments on ADC Therapeutics SA's Q1 2024 Earnings (NYSE:ADCT)marketbeat.com - April 18 at 5:59 AMShort Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 5.7%marketbeat.com - April 16 at 6:52 PMBuy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progressmarkets.businessinsider.com - April 16 at 11:05 AMHC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT)marketbeat.com - April 15 at 8:29 AMADC Therapeutics' (ADCT) "Buy" Rating Reiterated at Guggenheimmarketbeat.com - April 5 at 10:26 AMADC Therapeutics gains after data for lymphoma therapymsn.com - April 4 at 7:48 PMADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphomaglobenewswire.com - April 4 at 7:00 AMADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024globenewswire.com - April 3 at 7:00 AMADC Therapeutics Makes Grants to New Employees Under Inducement Planfinance.yahoo.com - April 1 at 8:10 PMADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Brokeragesmarketbeat.com - March 28 at 8:32 AMADC Therapeutics (NYSE:ADCT) Earns Buy Rating from Analysts at Guggenheimmarketbeat.com - March 28 at 8:28 AMADC Therapeutics (NYSE:ADCT) Earns "Outperform" Rating from Royal Bank of Canadamarketbeat.com - March 18 at 3:46 PMUS$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Resultsfinance.yahoo.com - March 16 at 1:49 PMADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 15 at 8:31 PMQ4 2023 ADC Therapeutics SA Earnings Callfinance.yahoo.com - March 14 at 10:46 AMADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Resetfinance.yahoo.com - March 13 at 1:21 PMmarketbeat.com - March 13 at 9:52 AMmarketbeat.com - March 13 at 9:48 AMmarketbeat.com - March 13 at 9:38 AMmarketbeat.com - March 13 at 9:34 AMADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatesglobenewswire.com - March 13 at 7:00 AMADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summitglobenewswire.com - March 6 at 7:15 AMADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024globenewswire.com - March 6 at 7:00 AMADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 5 at 5:45 PMADC Therapeutics SA: ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinanznachrichten.de - February 27 at 10:07 AMADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 27 at 7:00 AMADC Therapeutics (ADCT) Scheduled to Post Earnings on Mondaymarketbeat.com - February 25 at 7:32 AMADC Therapeutics (ADCT) Price Target Increased by 9.38% to 8.93msn.com - February 24 at 9:37 AMADC Therapeutics Stock (NYSE:ADCT), Quotes and News Summarybenzinga.com - February 23 at 9:19 AMEarnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Declinefinance.yahoo.com - February 21 at 3:39 PMEarnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Declinefinance.yahoo.com - February 20 at 1:52 PMThe 3 Biotech Stocks That Could Make Your February Unforgettablemsn.com - February 15 at 12:25 PMThe 3 Biotech Stocks That Could Make Your February Unforgettableinvestorplace.com - February 15 at 11:57 AM Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address 348 million Americans lives to END as we know it? (Ad)348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today... To see my free research, simply click here now. ADCT Media Mentions By Week ADCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.140.36▲Average Medical News Sentiment ADCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼152▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NATR News HROW News ESPR News RVNC News AMRN News LXRX News HRTX News MREO News MRSN News BMEA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.